WW International (WW) Q4 2024 earnings summary

Executive summary

• 2024 was a year of transition, with Q4 revenue down 10% year-over-year, driven by declines in the behavioral business but partially offset by 58% growth in the clinical segment.

• Ended 2024 with 3.3 million subscribers, down 12.2% year-over-year, but clinical subscribers grew 37.8% year-over-year to 92,000.

• Leadership changes included the appointment of Tara Comonte as permanent President and CEO and a new CFO.

• Adjusted gross margin reached a record 69.1% in Q4, up from 51.4% the prior year, driven by cost reductions and closure of the lower margin consumer products business.

• Launched new product features, including AI-powered tools, compounded semaglutide, and expanded access to registered dietitians.

Financial highlights

• Q4 2024 revenue was $184.4 million, down 10% year-over-year; full-year revenue was $785.9 million, down 11.6%.

• Q4 adjusted gross margin was 69.1%, up 771 basis points year-over-year.

• Q4 adjusted EBITDAS was $50.4 million (27.4% margin), up from $33.5 million (16.3% margin) in Q4 2023.

• Q4 net income was $25.1 million (13.6% margin), compared to a net loss of $88.1 million in Q4 2023.

• Cash and cash equivalents at year-end were $53 million.

Outlook and guidance

• 2025 is positioned as a reset year, focusing on stabilization and laying the groundwork for future growth.

• No full-year 2025 guidance provided; revenue faces a $45 million headwind due to a lower subscriber base.

• Cost savings initiatives on track to achieve $100 million run-rate savings by end of 2025.

• Marketing spend will be highest in Q1, with elevated CACs expected to persist.

• Fiscal 2025 includes a 53rd week, expected to have a modest negative impact on EBITDA and operating income.